Access the full text.
Sign up today, get DeepDyve free for 14 days.
Michael Savage, J. Douglas, D. Fischman, C. Pepine, S. King, J. Werner, S. Bailey, P. Overlie, S. Fenton, J. Brinker, M. Leon, S. Goldberg, R. Heuser, R. Smalling, R. Safian, M. Cleman, M. Buchbinder, David Snead, R. Rake, S. Gebhardt (1997)
Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators.The New England journal of medicine, 337 11
(2000)
Novel dosing regimen of eptifibatide in planned coronary stenting implantation: a randomized, placebo-controlled trial [published erratum appears in Lancet 2001; 357 (9265): 1370]Lancet, 356
(2002)
Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients [published erratum appears in BMJ 2002; 324 (7330): 141BMJ, 324
Deepak Vivekananthan, Deepak Bhatt, D. Chew, A. Chan, D. Moliterno, S. Ellis, E. Topol (2003)
Clopidogrel pretreatment prior to percutaneous coronary intervention attenuates periprocedural rise of C-reactive proteinJournal of the American College of Cardiology, 41
A. Grüntzig (1978)
TRANSLUMINAL DILATATION OF CORONARY-ARTERY STENOSISThe Lancet, 311
Wai-hong Chen, Pui-yin Lee, W. Ng, H. Tse, C. Lau (2004)
Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.Journal of the American College of Cardiology, 43 6
A. Mcnicol, S. Israels (2003)
Platelets and anti-platelet therapy.Journal of pharmacological sciences, 93 4
D. Chew, Deepak Bhatt (2002)
Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trialsInternal Medicine Journal, 32
W.W. O’Neill, M.B. Leon (2003)
Drug-eluting stents versus clinical benefitCirculation, 107
C.L. Grines, D.A. Cox, G.W. Stone (1999)
Coronary angioplasty with or without stent implantation for acute myocardial infarction: the Stent Primary Angioplasty in Myocardial Infarction Study GroupN Engl J Med, 341
M. Véjar, G. Fragasso, D. Hackett, D. Lipkin, A. Maseri, G. Born, G. Ciabattoni, C. Patrono (1990)
Dissociation of Platelet Activation and Spontaneous Myocardial Ischemia in Unstable AnginaThrombosis and Haemostasis, 63
A. Lincoff, N. Kleiman, D. Kereiakes, F. Feit, J. Bittl, J. Jackman, I. Sarembock, D. Cohen, D. Spriggs, R. Ebrahimi, G. Keren, J. Carr, E. Cohen, A. Betriu, W. Desmet, W. Rutsch, R. Wilcox, P. Feyter, A. Vahanian, E. Topol (2004)
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.JAMA, 292 6
J. Ferguson, R. Califf, E. Antman, Marc Cohen, C. Grines, S. Goodman, D. Kereiakes, A. Langer, K. Mahaffey, C. Nessel, P. Armstrong, Á. Avezum, P. Aylward, R. Becker, L. Biasucci, S. Borzak, J. Col, M. Frey, E. Fry, D. Gulba, S. Guneri, E. Gurfinkel, R. Harrington, J. Hochman, N. Kleiman, M. Leon, J. López-Sendón, C. Pepine, W. Rużyłło, S. Steinhubl, P. Teirstein, L. Toro-Figueroa, H. White (2004)
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.JAMA, 292 1
S. Mehta, S. Yusuf, R. Peters, M. Bertrand, B. Lewis, M. Natarajan, K. Malmberg, H. Rupprecht, F. Zhao, S. Chrolavicius, I. Copland, K. Fox (2001)
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE studyThe Lancet, 358
A. Kastrati, J. Mehilli, H. Schühlen, J. Dirschinger, F. Dotzer, J. Berg, F. Neumann, H. Bollwein, Christian Volmer, M. Gawaz, P. Berger, A. Schömig (2004)
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.The New England journal of medicine, 350 3
G. Mishkel, F. Aguirre, R. Ligon, K. Rocha-Singh, C. Lucore (1999)
Clopidogrel as adjunctive antiplatelet therapy during coronary stenting.Journal of the American College of Cardiology, 34 7
W.W. O’Neill, P. Serruys, M. Knudtson (2000)
The evaluation of oral xemilofiban in controlling thrombotic events (EXCITE): long term treatment with glycoprotein-receptor antagonist after percutaneous coronary revascularizationN Engl J Med, 342
J. Mehilli, A. Kastrati, H. Schühlen, A. Dibra, F. Dotzer, N. Beckerath, H. Bollwein, J. Pache, J. Dirschinger, Peter Berger, A. Schömig (2004)
Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of ClopidogrelCirculation, 110
A.R. Gruentzig (1978)
Translumination dilatation of coronary artery stenosis [letterLancet, I
J. O'shea, G. Hafley, Sally Greenberg, V. Hasselblad, T. Lorenz, M. Kitt, J. Strony, J. Tcheng (2001)
Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.JAMA, 285 19
E. Topol, J. Ferguson, H. Weisman, J. Tcheng, S. Ellis, N. Kleiman, R. Ivanhoe, Ann Wang, David Miller, K. Anderson, R. Califf (1997)
Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade With Percutaneous Coronary InterventionJAMA, 278
J. Mehilli, A. Kastrati, H. Schuhlen (2004)
Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel: the ISAR-SWEET investigatorsCirculation, 110
A. Bavry, D. Kumbhani, R. Quiroz, Suneil Ramchandani, S. Kenchaiah, E. Antman (2004)
Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature.The American journal of cardiology, 93 7
Raghava Gollapudi, P. Teirstein, D. Stevenson, R. Simon (2004)
Aspirin sensitivity: implications for patients with coronary artery disease.JAMA, 292 24
Sidney Smith, D. Faxon, W. Cascio, H. Schaff, T. Gardner, A. Jacobs, S. Nissen, R. Stouffer (2002)
Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group VI: revascularization in diabetic patients.Circulation, 105 18
C. Grines, D. Cox, G. Stone, Eulogio García, L. Mattos, A. Giambartolomei, B. Brodie, O. Madonna, M. Eijgelshoven, A. Lansky, W. O’Neill, M. Morice (1999)
Coronary Angioplasty with or without Stent Implantation for Acute Myocardial InfarctionThe New England Journal of Medicine, 341
J. Lefkovits, E. Plow, E. Topol (1995)
Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine.The New England journal of medicine, 332 23
Deepak Bhatt, E. Topol (2004)
Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.American heart journal, 148 2
(1997)
Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-IILancet, 349
A. Chan, D. Moliterno, P. Berger, G. Stone, Peter Dibattiste, S. Yakubov, S. Sapp, K. Wolski, Deepak Bhatt, E. Topol (2003)
Triple antiplatelet therapy during percutaneous coronary intervention is associated withimproved outcomes including one-year survivalJournal of the American College of Cardiology, 42
R. Erbel, M. Haude, H. Höpp, D. Franzen, H. Rupprecht, B. Heublein, K. Fischer, P. Jaegere, P. Serruys, W. Rutsch, P. Probst (1998)
Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group.The New England journal of medicine, 339 23
A.M. Lincoff, R.M. Califf, K.M. Anderson (1997)
Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularizationJ Am Coll Cardiol, 30
D. Chew, Deepak Bhatt, M. Robbins, M. Penn, J. Schneider, M. Lauer, E. Topol, S. Ellis (2001)
Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary InterventionCirculation: Journal of the American Heart Association, 104
A. Lincoff, R. Califf, K. Anderson, H. Weisman, F. Aguirre, N. Kleiman, R. Harrington, E. Topol (1997)
Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic ComplJournal of the American College of Cardiology, 30 1
W. O’Neill, M. Leon (2003)
Drug-eluting stents: costs versus clinical benefit.Circulation, 107 24
(1988)
Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.Journal of the American College of Cardiology, 12 6 Suppl A
M. Valgimigli, G. Percoco, D. Barbieri, F. Ferrari, G. Guardigli, G. Parrinello, Olga Soukhomovskaia, R. Ferrari (2004)
The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial.Journal of the American College of Cardiology, 44 1
M. Valgimigli, G. Percoco, P. Malagutti, G. Campo, F. Ferrari, D. Barbieri, G. Cicchitelli, E. Mcfadden, F. Merlini, L. Ansani, G. Guardigli, Alessandro Bettini, G. Parrinello, E. Boersma, R. Ferrari (2005)
Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.JAMA, 293 17
A. Peigney (2003)
Tougher ceramics with nanotubesNature Materials, 2
M. Bertrand, H. Rupprecht, P. Urban, A. Gershlick (2000)
Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS).Circulation, 102 6
W.E. Boden, R.A. O’Rourke, M.H. Crawford (1998)
Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy: Veterans Affairs Non Q-Wave Infarction Strategies in Hospital (VANQWISH) trial investigators [published erratum appears in N Engl J Med 1998; 339 (15): 1091N Engl J Med, 338
E. Topol, F. Neumann, G. Montalescot (2003)
A preferred reperfusion strategy for acute myocardial infarction.Journal of the American College of Cardiology, 42 11
H. Knobler, N. Savion, B. Shenkman, S. Kotev‐Emeth, D. Varon (1998)
Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients.Thrombosis research, 90 4
V. Mathew, D. Grill, C. Scott, J. Grantham, H. Ting, K. Garratt, D. Holmes (1999)
The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions.Journal of the American College of Cardiology, 34 4
S. Anand (2002)
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Eikelboom JW, Hirsh J, Weitz J, Johnston M, Yi Q, Yusuf S. Circulation 2002; 105: 1650- 1655.
C. Baigent, C. Sudlow, R. Collins, R. Peto, Antithromboci Collaborat (2002)
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ : British Medical Journal, 324
S. Silberman, Catherine Neukirch-Stoop, P. Steg (2005)
Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting.The American journal of cardiology, 95 4
E. Mcfadden, E. Stabile, E. Regar, E. Cheneau, A. Ong, T. Kinnaird, W. Suddath, N. Weissman, R. Torguson, K. Kent, A. Pichard, L. Satler, R. Waksman, P. Serruys (2004)
Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapyThe Lancet, 364
S. Smith, J. Dove, A. Jacobs, J. Kennedy, D. Kereiakes, M. Kern, R. Kuntz, J. Popma, H. Schaff, David Williams, R. Gibbons, J. Alpert, K. Eagle, D. Faxon, V. Fuster, T. Gardner, G. Gregoratos, Russell Ro, Sidney Smith (2001)
ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive SummaryJournal of the American College of Cardiology, 37
R. Storey (2001)
The P2Y 12 receptor as a therapeutic target in cardiovascular diseasePlatelets, 12
Deepak Bhatt, M. Roe, E. Peterson, Yun Li, A. Chen, R. Harrington, A. Greenbaum, P. Berger, C. Cannon, D. Cohen, C. Gibson, J. Saucedo, N. Kleiman, J. Hochman, W. Boden, R. Brindis, W. Peacock, Sidney Smith, C. Pollack, W. Gibier, E. Ohman (2004)
Utilization of Early Invasive Management Strategies for High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement InitiativeJAMA, 292
E. Topol, A. Lincoff, D. Kereiakes, Neal Kleiman, E. Cohen, J. Ferguson, J. Tcheng, S. Sapp, R. Califf (2002)
Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization.The American journal of medicine, 113 1
R. Altman, L. Carreras, R. Diaz, E. Figueroa, E. Paolasso, J. Parodi, J. Cade, G. Donnan, M. Eadie, T. Gavaghan, E. OSullivan, D. Parkin, Renny Jtg., C. Silagy, H. Vinazzer, F. Zekert, H. Adriaensen, J. Bertrandhardy, M. Bran, J. David, J. Dricot, E. Lavennepardonge, R. Limet, A. Lowenthal, M. Moriau, S. Schapira, P. Smets, J. Symoens, R. Verhaeghe, M. Verstraete, A. Atallah, H. Barnett, R. Batista, J. Blakely, J. Cairns, R. Cote, J. Crouch, G. Evans, J. Findlay, M. Gent, Y. Langlois, J. Leclerc, J. Norris, G. Pineo, P. Powers, R. Roberts, L. Schwartz, J. Sicurella, W. Taylor, P. Théroux, A. Turpie, R. Weisel, J. Cui, L. Liu, J. Pirk, C. Bay, G. Boysen, J. Knudsen, P. Petersen, P. Sørensen, H. Tønnesen, P. Harjola, J. Arcan, B. Balkau, J. Blanchard, J. Boissel, B. Boneu, M. Bousser, M. Brochier, M. Cloarec, G. Cribier, M. Dechavanne, P. Drouin, E. Eschwège, B. Guiraudchaumeil, R. Hugonot, A. Leizorovicz, Y. Loria, L. Michat, J. Mirouze, E. Panak, J. Pasteyer, A. Rascol, L. Revol, M. Roy, J. Sellés, G. Slama, C. Starkman, M. Teule, N. Thibult, M. Verry, F. Albert, K. Andrassy, K. Breddin, R. Eckel, A. Encke, J. Frohlich, B. Hartung, H. Heiss, H. Hess, B. Hofling, D. Krause, G. Latta, H. Linke, D. Loew, R. Lorenz, K. Middleton, G. Novak, M. Oldendorf, N. Pfluger, D. Raithel, R. Reuter, G. Schettler, J. Schnitker, W. Schoop, H. Stiegler, K. Uberla, G. Vogel, M. Weber, I. Welbers, E. Zeitler, G. Arapakis, T. Chan, C. Mok, R. Szabó, N. Misra, K. Reddy, G. FitzGerald, A. Apollonio, F. Balsano, A. Basellini, L. Candelise, M. Catalano, N. Ciavarella, G. Ciuffetti, S. Coccheri, M. Cortellaro, G. Corvi, V. Coto, G. Davı̀, R. Decaterina, T. Diperri, C. Fieschi, R. Gentile, L. Gregoratti, P. Gresele, M. Lavezzari, A. Libretti, B. Magnani, Nenci Gg, G. Pagano, C. Patrono, L. Pedrini, M. Pini, P. Prandoni, F. Romeo, F. Rovelli, G. Rudelli, G. Ruvolo, G. Signorini, G. Tognoni, F. Violi, T. Fujimori, M. Kageyama, T. Katsumura, S. Kitamura, K. Maeda, A. Suzuki, H. Tohgi, S. Uchiyama, H. Utsumi, A. Garcia, A. Algra, Denottolander Gjh., Kupper Ajf., J. Vangijn, H. Hart, L. Kappelle, P. Koudstaal, T. Lemmens, J. Lodder, M. Pannebakker, P. Serruys, A. Vandenbelt, J. Vandermeer, A. Vandervijgh, Verheugt Fwa, G. Veth, J. Dale, K. Johannessen, E. Thaulow, P. Popescu, N. Tiberiu, Aznar Jrd., E. Esmatjes, P. Guiteras, J. Lasierra, P. Lopeztrigo, A. Oriol, L. Pomar, E. Rocha, F. Sanchez, J. Sanchorieger, G. Sanz, Berglund Ulf., C. Blomstrand, M. Boberg, M. Britton, C. Elwin, C. Helmers, J. Holm, L. Janzon, S. Juulmoller, H. Mulec, J. Olsson, S. Persson, G. Rasmanis, A. Rosén, K. Samuelsson, J. Soreff, N. Wahlgren, L. Wallentin, H. Baur, M. Bokslag, A. Bollinger, B. Meier, M. Pfisterer, C. Sitthiamorn, E. Acheson, P. Appleby, A. Asscher, A. Aukland, C. Baigent, S. Bala, A. Barnett, P. Bell, S. Bews, Born Gvr., J. Branagan, N. Brooks, M. Brown, N. Browse, R. Capildeo, M. Carmalt, A. Carter, I. Chalmers, M. Clarke, R. Clarke, Clyne Cac., R. Collins, Cooke, G. Coutts, D. Cove, P. Crowther, W. Cuthbertson, D. Debono, C. Dickerson, J. Dickinson, R. Doll, J. Dormandy, D. Dunbabin, S. Ell, P. Elphinstone, P. Elwood, V. Englishby, B. Farrell, C. Fiskerstrand, M. Flather, T. Foley, T. Foulds, K. Fox, P. Franks, H. Fraser, T. Gardecki, M. Gawel, A. Gent, A. Gershlick, J. Godwin, M. Goldman, C. Gray, D. Gray, R. Gray, H. Handoll, G. Hankey, Harrison Mjg., N. Henderson, S. Heptinstall, S. Hobbiger, E. Jones, Jones Nag., S. Jost, D. Julian, J. Kellett, R. Kester, G. Lowe, J. Mackenzie, C. McCollum, G. Mead, T. Meade, D. Mendelow, J. Miller, G. Morris, C. Nichol, M. Noble, Obrien, M. Ogier, S. Parish, M. Parry, R. Peto, J. Powell, P. Pozzilli, N. Qizilbash, A. Rahman, S. Rajah, D. Richards, S. Richards, R. Ripley, V. Roberts, F. Rose, Russell Rwr., P. Rubin, C. Ruckley, P. Sandercock, Shaw Mdm., K. Shaw, J. Shelley, J. Slattery, P. Sleight, S. Smith, P. Stewartlong, P. Sweetnam, Tansey Mjb., H. Tindall, J. Turney, H. Tyler, N. Varey, M. Vessey, M. Walker, M. Walker, C. Warlow, R. Wilcox, H. Willems, E. Wood, E. Wynjones, H. Adams, B. Barton, R. Bedford, B. Bick, S. Bingham, B. Brown, T. Bryant, J. Buring, C. Cabot, P. Canner, J. Chesebro, O. Chrisman, G. Clagett, J. Colwell, M. Dyken, D. Ellis, W. Fields, C. Furberg, V. Fuster, S. Goldman, J. Granett, R. Green, D. Green, R. Hardy, L. Harker, W. Harris, R. Hart, W. Hass, C. Hennekens, D. Hill, M. Hume, M. Igloe, G. Johnson, S. Jonas, G. Knatterud, T. Kohler, N. Lembo, D. Lewis, E. Lockhart, P. Majerus, Mcenany, R. McKenna, J. Mehta, J. Meyer, B. Molony, T. Moritz, D. Nicoloff, G. Nycz, H. Ono, G. Pantely, S. Phillips, P. Ridker, J. Robertson, R. Rothbart, E. Salzman, R. Sautter, R. Schlant, J. Schoenberger, M. Sengekontacket, G. Sharma, P. Steele, K. Steinnagel, J. Stratton, J. Sullivan, G. Timmis, J. Toole, Walker, S. Weisman, C. White, M. Wirecki, D. Wombolt, R. Wong, S. Yusuf, K. Zadina, D. Zucker (1994)
Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 308
L. Schwartz, M. Bourassa, J. Lésperance, H. Aldridge, F. Kazim, V. Salvatori, M. Henderson, R. Bonan, P. David (1988)
Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.The New England journal of medicine, 318 26
D. Chew, Deepak Bhatt, S. Sapp, E. Topol (2001)
Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists: A Meta-Analysis of Phase III Multicenter Randomized TrialsCirculation: Journal of the American Heart Association, 103
E. Boersma, R. Harrington, D. Moliterno, H. White, P. Théroux, F. Werf, A. Torbal, P. Armstrong, L. Wallentin, R. Wilcox, J. Simes, R. Califf, E. Topol, M. Simoons (2002)
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trialsThe Lancet, 359
Deepak Bhatt (2004)
Aspirin resistance: more than just a laboratory curiosity.Journal of the American College of Cardiology, 43 6
G. Stone, C. Grines, D. Cox, Eulogio García, J. Tcheng, J. Griffin, G. Guagliumi, T. Stuckey, M. Turco, J. Carroll, B. Rutherford, A. Lansky (2002)
Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.The New England journal of medicine, 346 13
H. Anderson, R. Shaw, R. Brindis, K. Hewitt, R. Krone, P. Block, C. McKay, W. Weintraub (2002)
A contemporary overview of percutaneous coronary interventions. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR).Journal of the American College of Cardiology, 39 7
Epilog Investigators (1997)
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.The New England journal of medicine, 336 24
S.C. Smith, J.T. Dove, A.K. Jacobs (2001)
ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): Executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). Endorsed by the Society for Cardiac Angiography and InterventionsCirculation, 103
E.J. Topol, D.B. Mark, A.M. Lincoff (1999)
Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stentingLancet, 354
A.R. Gruentzig, A. Senning, W.E. Siegenthaler (1979)
Nonoperative dilatation of coronary-artery stenosisN Engl J Med, 301
David Lee, N. Herity, B. Hiatt, W. Fearon, M. Rezaee, A. Carter, Michelle Huston, D. Schreiber, Peter Dibattiste, A. Yeung (2003)
Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition With Tirofiban Before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot TrialCirculation: Journal of the American Heart Association, 107
E. Topol, D. Easton, R. Harrington, P. Amarenco, R. Califf, Carmen Graffagnino, S. Davis, H. Diener, James Ferguson, D. Fitzgerald, J. Granett, A. Shuaib, P. Koudstaal, P. Théroux, F. Werf, Kristina Sigmon, K. Pieper, M. Vallée, J. Willerson (2003)
Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular DiseaseCirculation: Journal of the American Heart Association, 108
T. Investigators (1998)
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.Lancet, 352 9122
M. Leon, D. Baim, J. Popma, P. Gordon, D. Cutlip, K. Ho, A. Giambartolomei, D. Diver, D. Lasorda, David Williams, S. Pocock, R. Kuntz (1998)
A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery StentingThe New England Journal of Medicine, 339
D. Chew, Deepak Bhatt (2001)
Oral glycoprotein IIb/IIIa antagonists in coronary artery diseaseCurrent Cardiology Reports, 3
A. Jeremias, Deepak Bhatt, D. Chew, K. Ziada, A. Albirini, S. Brener, A. Lincoff, E. Topol, S. Ellis (2002)
Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency.The American journal of cardiology, 89 10
D. Tschoepe, P. Roesen, L. Kaufmann, S. Schauseil, B. Kehrel, H. Ostermann, F. Gries (1990)
Evidence for abnormal platelet glycoprotein expression in diabetes mellitusEuropean Journal of Clinical Investigation, 20
J.C. O’shea, G.E. Hafley, S. P. g. I. i. b. w. e. i. c. s. i. t. E. trial. Greenberg (2001)
A randomized controlled trialJAMA, 285
M. Taniuchi, Howard Kurz, J. Lasala (2001)
Randomized Comparison of Ticlopidine and Clopidogrel After Intracoronary Stent Implantation in a Broad Patient PopulationCirculation: Journal of the American Heart Association, 104
J. Bittl, J. Strony, J. Brinker, W. Ahmed, C. Meckel, B. Chaitman, J. Maraganore, E. Deutsch, B. Adelman, B. Adelman (1995)
Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators.The New England journal of medicine, 333 12
R. Storey, H. Judge, R. Wilcox, S. Heptinstall (2002)
Inhibition of ADP-induced P-selectin Expression and Platelet-Leukocyte Conjugate Formation by Clopidogrel and the P2Y12 Receptor Antagonist AR-C69931MX but not AspirinThrombosis and Haemostasis, 88
Deepak Bhatt, M. Bertrand, P. Berger, P. L'allier, I. Moussa, J. Moses, G. Dangas, M. Taniuchi, J. Lasala, D. Holmes, S. Ellis, E. Topol (2002)
Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting.Journal of the American College of Cardiology, 39 1
M. Roffi, D. Mukherjee, D. Chew, Deepak Bhatt, L. Cho, M. Robbins, K. Ziada, D. Brennan, S. Ellis, E. Topol (2002)
Lack of Benefit From Intravenous Platelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment for Percutaneous Interventions of Aortocoronary Bypass Grafts: A Pooled Analysis of Five Randomized Clinical TrialsCirculation: Journal of the American Heart Association, 106
C. Hamm, C. Heeschen, B. Goldmann, A. Vahanian, J. Adgey, C. Miguel, W. Rutsch, J. Berger, J. Kootstra, M. Simoons (1999)
Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.The New England journal of medicine, 340 21
S.J. Brener, L.A. Barr, J.E. Burchenal (1998)
Randomized, placebo controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction: ReoPro And Primary PTCA Organization and Randomized Trial (RAPPORT) investigatorsCirculation, 98
M. Dalby, G. Montalescot, C. Sollier, E. Vicaut, T. Soulat, J. Collet, R. Choussat, Vanessa Gallois, G. Drobinski, L. Drouet, Daniel Thomas (2004)
Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study.Journal of the American College of Cardiology, 43 2
(1997)
IIIa receptor blockade and low-dose heparin during percutaneous coronary intervention: the EPILOG investigatorsN Engl J Med, 336
S. Servi, P. Hall, A. Gaglione (1999)
Stent thrombosis: incidence and related factors in the Registro Impianto Stent Endocoronarico (RISE) registryCatheter Cardiovasc Interv, 46
M. Simoons (2001)
Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trialThe Lancet, 357
H. Anderson, C. Cannon, P. Stone, David Williams, C. Mccabe, G. Knatterud, B. Thompson, J. Willerson, E. Braunwald (1995)
One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction.Journal of the American College of Cardiology, 26 7
B.A. Hout, L. Bownman, D.J. Zelinger (1998)
Cost and effects in therapy for acute coronary syndromesEur Heart J, 19
(2002)
Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromesCirculation, 105
E. Boersma, K. Akkerhuis, P. Théroux, R. Califf, E. Topol, M. Simoons (1999)
Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.Circulation, 100 20
S.C. Smith, D. Faxon, W. Cascio (2002)
Diabetes and cardiovascular disease writing group VI: revascularization in diabetic patientsCirculation, 105
W. O’Neill, C. Grines (2002)
Surgery or stent? The gap continues to narrowThe Lancet, 360
M. Babapulle, L. Joseph, P. Belisle, J. Brophy, M. Eisenberg (2004)
A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stentsAcc Current Journal Review, 13
F. Cipollone, P. Patrignani, A. Greco, M. Panara, R. Padovano, F. Cuccurullo, C. Patrono, A. Rebuzzi, G. Liuzzo, G. Quaranta, A. Maseri (1997)
Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina.Circulation, 96 4
G. Danzi, M. Sesana, C. Capuano, L. Mauri, P. Centurini, R. Baglini (2004)
Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function.The American journal of cardiology, 94 1
H. Gardner (2002)
Too Many ChoicesNew York Review of Books, 49
Integrilin Thrombosis-II (1997)
Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-IIThe Lancet, 349
J. Eikelboom, J. Hirsh, J. Weitz, M. Johnston, Q. Yi, S. Yusuf (2002)
Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular EventsCirculation: Journal of the American Heart Association, 105
K. Moshfegh, Maurice Redondo, F. Julmy, Walter Wuillemin, Mathias Gebauer, André Haeberli, Beat Meyer (2000)
Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy.Journal of the American College of Cardiology, 36 3
(1994)
Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients: Antiplatelet Trialists’ Collaboration [published erratum appears in BMJBMJ, 308
Deepak Bhatt, E. Topol (2000)
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.JAMA, 284 12
I. Moussa, M. Oetgen, G. Roubin, A. Colombo, Xangdong Wang, S. Iyer, Roberta Maida, M. Collins, E. Kreps, J. Moses (1999)
Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.Circulation, 99 18
E. Topol, J. Ferguson, H. Weisman, J. Tcheng, Stephen Ellis, N. Kleiman, R. Ivanhoe, Ann Wang, David Miller, K. Anderson, R. Califf (1997)
Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.JAMA, 278 6
S. Servi, S. Repetto, S. Klugmann, I. Bossi, A. Colombo, R. Piva, L. Giommi, A. Bartorelli, A. Fontanelli, G. Mariani, C. Klersy (1999)
Stent thrombosis: Incidence and related factors in the R.I.S.E. registry (Registro Impianto Stent Endocoronarico)Catheterization and Cardiovascular Interventions, 46
H. Schühlen, A. Kastrati, J. Mehilli, J. Hausleiter, J. Dirschinger, F. Dotzer, H. Bollwein, A. Schömig (1997)
Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loadAmerican heart journal, 151 6
Michael Savage, D. Fischman, R. Rake, M. Leon, R. Schatz, I. Penn, M. Nobuyoshi, J. Moses, J. Hirshfeld, R. Heuser, D. Baim, M. Cleman, J. Brinker, S. Gebhardt, S. Goldberg (1998)
Efficacy of coronary stenting versus balloon angioplasty in small coronary arteries. Stent Restenosis Study (STRESS) Investigators.Journal of the American College of Cardiology, 31 2
S.R. Steinhubl, W.A. Tan, J.M. Foody (1999)
Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting: the Evaluation of Platelet IIb/IIIa Inhibitor for STENTing (EPISTENT) investigatorsJAMA, 281
P. Deedwania (2000)
Endothelium: a new target for cardiovascular therapeutics.Journal of the American College of Cardiology, 35 1
A. Sugidachi, F. Asai, T. Ogawa, Teruhiko Inoue, H. Koike (2000)
The in vivo pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist propertiesBritish Journal of Pharmacology, 129
W. Boden, R. O'rourke, M. Crawford, A. Blaustein, P. Deedwania, R. Zoble, L. Wexler, R. Kleiger, C. Pepine, D. Ferry, B. Chow, P. Lavori (1998)
Correction: Outcomes in Patients with Acute Non-Q-Wave Myocardial Infarction Randomly Assigned to an Invasive as Compared with a Conservative Management Strategy.The New England journal of medicine, 339 15
T. Investigators (1997)
Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.Circulation, 96 5
D. Fischman, M. Leon, D. Baim, R. Schatz, M. Savage, I. Penn, K. Detre, L. Veltri, D. Ricci, M. Nobuyoshi (1994)
A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.The New England journal of medicine, 331 8
D. Antoniucci, Alfredo Rodríguez, A. Hempel, R. Valenti, A. Migliorini, Federico Vigo, G. Parodi, C. Fernandez-Pereira, G. Moschi, A. Bartorelli, G. Santoro, L. Bolognese, A. Colombo (2003)
A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction.Journal of the American College of Cardiology, 42 11
E. Antman, D. Anbe, P. Armstrong, Eric Bates, L. Green, M. Hand, J. Hochman, H. Krumholz, F. Kushner, G. Lamas, C. Mullany, J. Ornato, D. Pearle, M. Sloan, Sidney Smith (2004)
ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients WiThe Canadian journal of cardiology, 20 10
D.J. Cohen, T. Lavelle, H.-L. Chen (2003)
Cost-effectiveness of bivalirudin with provisional glycoprotein IIb/IIIa inhibition vs heparin and routine glycoprotein IIb/IIIa inhibition for contemporary PCI: results from the REPLACE II trialCirculation, 108Suppl.IV
A. Grüntzig, Å. Senning, W. Siegenthaler (1979)
Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty.The New England journal of medicine, 301 2
G. Wong, R. Giugliano, E. Antman (2003)
Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention.JAMA, 289 3
W. O’Neill, P. Serruys, M. Knudtson, G. Es, G. Timmis, C. Zwaan, J. Kleiman, J. Gong, E. Roecker, R. Dreiling, J. Alexander, R. Anders (2000)
Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events.The New England journal of medicine, 342 18
Jeffrey Popma, P. Berger, E. Ohman, Robert Harrington, C. Grines, Jeffrey Weitz (2004)
Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest, 126 3 Suppl
Deepak Bhatt, E. Topol (2003)
Scientific and therapeutic advances in antiplatelet therapyNature Reviews Drug Discovery, 2
E. Topol, D. Moliterno, H. Herrmann, E. Powers, C. Grines, D. Cohen, E. Cohen, M. Bertrand, Franz‐Josef Neumann, G. Stone, Peter Dibattiste, S. Yakubov, P. Delucca, L. Demopoulos (2001)
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.The New England journal of medicine, 344 25
L. Wallentin, E. Swahn, F. Kontny, S. Husted, B. Lagerqvist, E. Ståhle (1999)
Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre studyThe Lancet, 354
G. Dangas, R. Mehran, A. Abizaid, B. Curry, A. Lansky, K. Kent, A. Pichard, L. Satler, M. Paliou, G. Stone, M. Leon (2001)
Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting.The American journal of cardiology, 87 4
J.J. Ferguson, R.M. Califf, E.M. Antman (2004)
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST segment elevation acute coronary syndromes managed with an intended early invasive strategy: the SYNERGY trial investigatorsJAMA, 292
D. Chew, Deepak Bhatt, M. Robbins, D. Mukherjee, M. Roffi, J. Schneider, E. Topol, S. Ellis (2001)
Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein.The American journal of cardiology, 88 6
C.W. Hamm, C. Heeschen, B. Goldmann (1999)
Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levelsN Engl J Med, 340
S. Yusuf, F. Zhao, S. Mehta, S. Chrolavicius, G. Tognoni, K. Fox, Clopidogrel Investigators (2001)
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.The New England journal of medicine, 345 7
Michael Savage, S. Goldberg, A. Bove, E. Deutsch, G. Vetrovec, R. Macdonald, T. Bass, J. Margolis, H. Whitworth, A. Taussig, J. Hirshfeld, M. Cowley, James Hill, Ronald Marks, D. Fischman, E. Handberg, H. Herrmann, C. Pepine (1995)
Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II)Circulation, 92 11
Franz‐Josef Neumann, A. Kastrati, C. Schmitt, R. Blasini, M. Hadamitzky, J. Mehilli, M. Gawaz, M. Schleef, M. Seyfarth, J. Dirschinger, A. Schömig (2000)
Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction.Journal of the American College of Cardiology, 35 4
W. Batchelor, T. Tolleson, Yao Huang, R. Larsen, Mantell Rm, Patricia Dillard, M. Davidian, Daowen Zhang, W. Cantor, M. Sketch, E. Ohman, J. Zidar, D. Gretler, Peter Dibattiste, J. Tcheng, R. Califf, R. Harrington (2002)
Randomized COMparison of Platelet Inhibition With Abciximab, TiRofiban and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes: The COMPARE TrialCirculation: Journal of the American Heart Association, 106
S. Steinhubl, W. Tan, J. Foody, E. Topol (1999)
Incidence and Clinical Course of Thrombotic Thrombocytopenic Purpura Due to Ticlopidine Following Coronary StentingJAMA, 281
(1998)
Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization NetworkCirculation, 97
A. Lincoff, J. Bittl, R. Harrington, F. Feit, N. Kleiman, J. Jackman, I. Sarembock, D. Cohen, D. Spriggs, R. Ebrahimi, G. Keren, J. Carr, E. Cohen, A. Betriu, W. Desmet, D. Kereiakes, W. Rutsch, R. Wilcox, P. Feyter, A. Vahanian, E. Topol (2003)
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.JAMA, 289 7
M. Stadius (2004)
Diminishing returns...and too many choices...the saga of pharmacologic therapy to reduce the complications of percutaneous coronary intervention.Journal of the American College of Cardiology, 44 1
A. Assali, J. Salloum, S. Sdringola, A. Moustapha, Mohammad Ghani, S. Hale, G. Schroth, G. Schroth, K. Fujise, H. Anderson, R. Smalling, O. Rosales (2001)
Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).The American journal of cardiology, 88 8
C. Patrono, F. Bachmann, C. Baigent, C. Bode, R. Caterina, B. Charbonnier, D. Fitzgerald, J. Hirsh, S. Husted, J. Kvasnička, G. Montalescot, L. Rodríguez, F. Verheugt, J. Vermylen, L. Wallentin, S. Priori, María García, J. Blanc, A. Budaj, M. Cowie, V. Dean, J. Deckers, Enrique Burgos, J. Lekakis, B. Lindahl, G. Mazzotta, J. Morais, A. Oto, O. Smiseth, Rafael Ferreira, P. Steg, Frederico Teixeira, R. Wilcox (2004)
Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology.European heart journal, 25 2
D. Cutlip, C. Cove, D. Irons, V. Kalaria, M. Le, H. Cronmiller, L. Caufield, R. Pomerantz, F. Ling (2001)
Emergency room administration of eptifibatide before primary angioplasty for ST elevation acute myocardial infarction and its effect on baseline coronary flow and procedure outcomes.The American journal of cardiology, 88 1
E. Topol, D. Mark, A. Lincoff, E. Cohen, J. Burton, N. Kleiman, David Talley, S. Sapp, J. Booth, C. Cabot, K. Anderson, R. Califf (1999)
Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trialThe Lancet, 354
M. Lichtman, J. Spivak, L. Boxer, S. Shattil, E. Henderson (2000)
Commentary on and reprint of EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) Investigators, The, Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, in New England Journal of Medicine (1994) 330:956–961
P. Berger, M. Bell, C. Rihal, Henry Ting, G. Barsness, K. Garratt, Victoria Bellot, V. Mathew, S. Melby, L. Hammes, D. Grill, D. Holmes (1999)
Clopidogrel versus ticlopidine after intracoronary stent placement.Journal of the American College of Cardiology, 34 7
T. Ryan (1988)
Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty).Journal of the American College of Cardiology, 12 2
C. Müller, H. Büttner, J. Petersen, H. Roskamm (2000)
A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents.Circulation, 101 6
R. Erbel, M. Haude, H. Höpp, D. Franzen, H. Rupprecht, B. Heublein, K. Fischer, Peter Jaegere, P. Serruys, W. Rutsch, P. Probst (1999)
Coronary-Artery Stenting Compared with Balloon Angioplasty for Restenosis After Initial Balloon AngioplastySurvey of Anesthesiology, 43
E. Braunwald, E.M. Antman, J.W. Beasley (2002)
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: 2002. Summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable AnginaCirculation, 106
P. Gum, K. Kottke-Marchant, P. Welsh, Jennifer White, E. Topol (2003)
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.Journal of the American College of Cardiology, 41 6
C. Cannon, W. Weintraub, L. Demopoulos, R. Vicari, M. Frey, N. Lakkis, Franz‐Josef Neumann, D. Robertson, P. Delucca, Peter Dibattiste, C. Gibson, E. Braunwald (2001)
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.The New England journal of medicine, 344 25
M. Roffi, D. Chew, D. Mukherjee, Deepak Bhatt, J. White, C. Heeschen, C. Hamm, D. Moliterno, R. Califf, H. White, N. Kleiman, P. Théroux, E. Topol (2001)
Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary SyndromesCirculation: Journal of the American Heart Association, 104
G. Montalescot, P. Barragan, O. Wittenberg, P. Ecollan, S. Elhadad, Ph Villain, Jean-Marc Boulenc, M. Morice, L. Maillard, M. Pansieri, R. Choussat, P. Pinton (2001)
Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.The New England journal of medicine, 344 25
(2000)
ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: executive summary and recommendations.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 51 4
M. Babapulle, L. Joseph, P. Belisle, J. Brophy, M. Eisenberg (2004)
A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stentsThe Lancet, 364
S. Steinhubl, Peter Berger, J. III, Edward Fry, A. Delago, C. Wilmer, E. Topol (2002)
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.JAMA, 288 19
A. Calver, L. Blows, S. Harmer, K. Dawkins, H. Gray, J. Morgan, I. Simpson (2000)
Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.American heart journal, 140 3
D.P. Lee, N.A. Herity, B.L. Hiatt (2003)
Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomesCirculation, 107
M. Roffi, D. Mukherjee, D.P. Chew (2002)
Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass graftsCirculation, 106
G. Patti, G. Colonna, V. Pasceri, L. Pepe, A. Montinaro, G. Sciascio (2005)
Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study*Circulation, 111
G. Stone, M. Bertrand, A. Colombo, G. Dangas, M. Farkouh, F. Feit, A. Lansky, A. Lincoff, R. Mehran, J. Moses, M. Ohman, H. White (2004)
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.American heart journal, 148 5
D. Walter, S. Fichtlscherer, M. Sellwig, W. Auch‐Schwelk, V. Schächinger, A. Zeiher (2001)
Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation.Journal of the American College of Cardiology, 37 3
Mun Hong, Roxana Mehran, G. Dangas, G. Mintz, Alexandra Lansky, K. Kent, A. Pichard, L. Satler, G. Stone, M. Leon (2001)
Are we making progress with percutaneous saphenous vein graft treatment? A comparison of 1990 to 1994 and 1995 to 1998 results.Journal of the American College of Cardiology, 38 1
E. Karvouni, D. Katritsis, J. Ioannidis (2003)
Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions.Journal of the American College of Cardiology, 41 1
S. Brener, L. Barr, J. Burchenal, S. Katz, B. George, A. Jones, E. Cohen, Phillip Gainey, H. White, H. Cheek, J. Moses, D. Moliterno, M. Effron, E. Topol (1998)
Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial InfarctionCirculation, 98
E. Iwase, M. Tawata, Kaoru Aida, Yukio Ozaki, Shoji Kume, K. Satoh, Ruomei Qi, Toshimasa Onaya (1998)
A cross-sectional evaluation of spontaneous platelet aggregation in relation to complications in patients with type II diabetes mellitus.Metabolism: clinical and experimental, 47 6
M. Dennis (1996)
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering CommitteeThe Lancet, 348
Deepak Bhatt, S. Marso, A. Lincoff, K. Wolski, S. Ellis, E. Topol (2000)
Abciximab reduces mortality in diabetics following percutaneous coronary intervention.Journal of the American College of Cardiology, 35 4
X. Zhao, P. Théroux, S. Snapinn, F. Sax (1999)
Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and sCirculation, 100 15
M.B. Leon, D.S. Baim, J.J. Popma (1998)
A clinical trial comparing three antithrombotic-drug regimens after coronary artery stenting: the Stent Anticoagulation Restenosis Study investigatorsN Engl J Med, 339
Antiplatelet agents play a major role in patients undergoing percutaneous coronary intervention (PCI). Stent thrombosis and the demand for improved clinical outcomes have driven the need for aggressive antiplatelet and anticoagulant regimens and newer, more efficacious, therapies. The benefits of intravenous glycoprotein (GP) IIb/IIIa antagonists and clopidogrel in high-risk patients undergoing PCI appear complementary. In low- to intermediate-risk patients, clopidogrel pre-treatment and a maintenance dose of aspirin + clopidogrel for at least 1 year after PCI are supported by the data, although the optimal duration of clopidogrel treatment beyond 1 year remains hotly contested. The next generation of clinical trials will examine the benefits of antiplatelet and antithrombotic agents as adjunctive therapy with drug-eluting stents. A better understanding of our patients’ overall risk will add to procedural success and more durable outcomes.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 20, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.